Emergent BioSolutions (EBS) Receivables - Other (2017 - 2026)

Emergent BioSolutions has reported Receivables - Other for 10 years, with the latest figure at $21.2 million in Q2 2026.

• On a quarterly basis, Receivables - Other fell 7.42% year-over-year to $21.2 million in Q2 2026; TTM through Jun 2026 was $21.2 million, a 7.42% decrease from a year earlier, with the FY2025 full-year figure at $18.2 million, down 7.14% from the prior year.
• Receivables - Other was $21.2 million for Q2 2026 at Emergent BioSolutions, up from $18.3 million in the prior quarter.
• The five-year high for Receivables - Other was $82.5 million in Q2 2024, with the low at $18.2 million in Q4 2025.
• Average Receivables - Other over 5 years is $42.2 million, with a median of $45.7 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Receivables - Other jumped 59.27% in 2024, then slumped 72.24% in 2025.
• Over 5 years, Receivables - Other stood at $57.2 million in 2022, then decreased by 10.14% to $51.4 million in 2023, then slumped by 61.87% to $19.6 million in 2024, then slipped by 7.14% to $18.2 million in 2025, then rose by 16.48% to $21.2 million in 2026.
• The last three Receivables - Other figures came in at $21.2 million (Q2 2026), $18.3 million (Q1 2026), and $18.2 million (Q4 2025), per Business Quant data.